SCHEMBL6401291

SCHEMBL6401291

O=C(Nc1ccc(Oc2ccncc2)cc1)Oc1cccc2cccnc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.71
L3MBTL1 Q9Y468 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
FAAH O00519 1/20 0.49
RAF1 P04049 2/20 0.48
LMNA P02545 4/20 0.48
METAP2 P50579 1/20 0.48
METAP1 P53582 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
MAPT P10636 4/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47
MECP2 P51608 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412821 0.92 HSP90AA1 (0.81) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL6402938 0.90 HSP90AA1 (0.67) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL5254903 0.86 HSP90AA1 (0.72) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL7360935 0.83 HSP90AA1 (1.00) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL5252574 0.83 HSP90AA1 (0.71) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL4409556 0.83 HSP90AA1 (0.79) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL5245061 0.81 HSP90AA1 (0.85) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL4422323 0.81 HSP90AA1 (0.68) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL4411378 0.81 HSP90AA1 (0.68) HSP90AA1FAAHMAPTMEN1KMT2A
SCHEMBL4413967 0.81 HSP90AA1 (0.74) HSP90AA1L3MBTL1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949574-B2 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-27 US disclosed
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2005-06-16 US disclosed
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 HSP90AA1 1769/4885L3MBTL1 2799/4885SMN1; SMN2 1362/4885
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 HSP90AA1 1769/4885L3MBTL1 2799/4885SMN1; SMN2 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.